[go: up one dir, main page]

WO2008009859A3 - Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée - Google Patents

Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée Download PDF

Info

Publication number
WO2008009859A3
WO2008009859A3 PCT/FR2007/051686 FR2007051686W WO2008009859A3 WO 2008009859 A3 WO2008009859 A3 WO 2008009859A3 FR 2007051686 W FR2007051686 W FR 2007051686W WO 2008009859 A3 WO2008009859 A3 WO 2008009859A3
Authority
WO
WIPO (PCT)
Prior art keywords
acne
treatment
scarb
hyperseborrhoea
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051686
Other languages
English (en)
Other versions
WO2008009859A2 (fr
Inventor
Fernand Labrie
Ezequiel L Calvo
Jerome Aubert
Isabelle Carlavan
Pascal Collette
Johannes Voegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to CA002656844A priority Critical patent/CA2656844A1/fr
Priority to EP07823605A priority patent/EP2044435A2/fr
Publication of WO2008009859A2 publication Critical patent/WO2008009859A2/fr
Publication of WO2008009859A3 publication Critical patent/WO2008009859A3/fr
Anticipated expiration legal-status Critical
Priority to US12/320,166 priority patent/US20090246776A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne une méthode in vitro de criblage de composés candidats pour le traitement préventif ou curatif de l'acné, comprenant la détermination de la capacité d'un composé à moduler l'expression ou l'activité du récepteur SCARB-1, ainsi que l'utilisation de modulateurs de l'expression ou de l'activité de ce récepteur pour le traitement de l'acné ou des désordres cutanés associés à une hyperséborrhée. L'invention concerne aussi des méthodes de diagnostic ou pronostic in vitro de ces pathologies.
PCT/FR2007/051686 2006-07-19 2007-07-18 Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée Ceased WO2008009859A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002656844A CA2656844A1 (fr) 2006-07-19 2007-07-18 Modulateurs de scarb-1 dans le traitement de l'acne ou de l'hyperseborrhee
EP07823605A EP2044435A2 (fr) 2006-07-19 2007-07-18 Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
US12/320,166 US20090246776A1 (en) 2006-07-19 2009-01-21 Modulators of scarb-1 for treating acne or hyperseborrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0653034A FR2904004B1 (fr) 2006-07-19 2006-07-19 Modulateurs de scarb-1 dans le traitement de l'acne ou de l'hyperseborrhee
FR0653034 2006-07-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/320,166 Continuation US20090246776A1 (en) 2006-07-19 2009-01-21 Modulators of scarb-1 for treating acne or hyperseborrhea

Publications (2)

Publication Number Publication Date
WO2008009859A2 WO2008009859A2 (fr) 2008-01-24
WO2008009859A3 true WO2008009859A3 (fr) 2008-03-13

Family

ID=37668112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051686 Ceased WO2008009859A2 (fr) 2006-07-19 2007-07-18 Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée

Country Status (5)

Country Link
US (1) US20090246776A1 (fr)
EP (1) EP2044435A2 (fr)
CA (1) CA2656844A1 (fr)
FR (1) FR2904004B1 (fr)
WO (1) WO2008009859A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2938337A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de mcam dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938333A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de cidea dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938342A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
FR2938336A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de gos2 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998141A (en) * 1997-07-10 1999-12-07 Millennium Pharmaceuticals, Inc. Intronic and polymorphic SR-BI nucleic acids and uses therefor
WO2002095034A2 (fr) * 2001-05-23 2002-11-28 Cytochroma Inc. Cytochrome p450 metabolisant l'acide retinoique
WO2005100998A2 (fr) * 2004-04-16 2005-10-27 Europroteome Ag Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654013A (en) * 1995-03-13 1997-08-05 Taylor; Lesli A. Method for treating rosacea
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
US5965790A (en) * 1997-03-06 1999-10-12 Millennium Pharmaceuticals, Inc. SR-BI regulatory sequences and therapeutic methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998141A (en) * 1997-07-10 1999-12-07 Millennium Pharmaceuticals, Inc. Intronic and polymorphic SR-BI nucleic acids and uses therefor
WO2002095034A2 (fr) * 2001-05-23 2002-11-28 Cytochroma Inc. Cytochrome p450 metabolisant l'acide retinoique
WO2005100998A2 (fr) * 2004-04-16 2005-10-27 Europroteome Ag Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRIVEDI NISHIT R ET AL: "Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY MAY 2006, vol. 126, no. 5, May 2006 (2006-05-01), pages 1071 - 1079, XP002417785, ISSN: 0022-202X *

Also Published As

Publication number Publication date
EP2044435A2 (fr) 2009-04-08
WO2008009859A2 (fr) 2008-01-24
FR2904004A1 (fr) 2008-01-25
US20090246776A1 (en) 2009-10-01
FR2904004B1 (fr) 2008-09-05
CA2656844A1 (fr) 2008-01-24

Similar Documents

Publication Publication Date Title
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
MX2009007023A (es) Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2009124330A3 (fr) Traitement de maladies tumorales
BRPI0811581A2 (pt) Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
WO2007123722A3 (fr) Procedes de prevision et de pronostic de cancer, et surveillance d'une therapie anticancereuse
WO2010045490A3 (fr) Mappage sur hyperespace multidimensionnel de biomarqueur humain pour des troubles dépressifs
WO2005074985A3 (fr) Methodes de modulation de cd200
WO2008009855A3 (fr) Modulateurs de sc4mol dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009856A3 (fr) Modulateurs de hsd17b7 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009859A3 (fr) Modulateurs de scarb-1 dans le traitement de l'acné ou de l'hyperséborrhée
WO2007101063A3 (fr) Traitement de troubles liés au développement
WO2008009857A3 (fr) Modulateurs de la udp-glucose céramide glucosyltransférase dans le traitement de l'acné ou de l'hyperkératinisation
WO2009017719A8 (fr) Modulateurs du récepteur ccr9 et leurs procédés d'utilisation
WO2008009854A3 (fr) Modulateurs du transporteur abcd3 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009858A3 (fr) Modulateurs de elovl5 dans le traitement de l'acné ou de l'hyperséborrhée
WO2008009852A3 (fr) Modulateurs de la lanostérol synthétase dans le traitement de l'acné ou de l'hyperséborrhée
WO2006129867A3 (fr) Expression accrue de l'arn de lactoferrine par la lacritine
WO2006009950A3 (fr) Genes aldo utilises comme modificateurs de la voie igf et procedes d'utilisation
WO2007002188A3 (fr) Genes mptenakt en tant genes modificateurs de la voie pten/akt et methodes d'utilisation
WO2009135910A3 (fr) Modulateurs de mcam dans le traitement de l'acné, de dermatite séborrhéique ou d'hyperséborrhée
WO2009004247A3 (fr) Inhibiteurs de tace dans le traitement de l'acne
WO2011071916A3 (fr) Sr-bi en tant qu'indicateur de la stérilité de la femme et de la réactivité au traitement
WO2009135917A3 (fr) Cribblage de modulateurs de cyp2b15 et/ou de gpd1 pour traiter l'acné, la dermatite séborrhéique ou l'hyperséborrhée
WO2006009928A3 (fr) Galnts comme modificateurs du chemin igfr et procedes d'utilisation
WO2008016996A3 (fr) Procédés de modulation de la mémoire métabolique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07823605

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007823605

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2656844

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU